Latest Period
Q2 2026
CUSIP: 68764Y207
Latest Period
Q2 2026
Institutions Reporting
30
Shares (Excl. Options)
2,896,073
Price
$1.90
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
Latest holder context comes from 30 institutions filings for Q2 2026.
Security key
68764Y207
Latest holder period
Q2 2026
13F holders
30
13D/G owners
3
CIK / CUSIP context first
Broader feeds
Open recent reporting periods for CUSIP 68764Y207:
13D/G owners
Large-stake holder rows connected to Schedule 13D/G evidence.
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| SATTERFIELD THOMAS A JR | 9.4% | +58% | $5,296,658 | +$3,141,967 | 3,115,681 | +146% | Thomas A. Satterfield, Jr. | 30 Jun 2025 |
| Auerbach Shalom | 8.5% | -14% | $4,899,953 | -$18,300 | 2,677,570 | -0.37% | Shalom Auerbach | 29 Jul 2025 |
| Ayala Pharmaceuticals, Inc. | 10% | $4,328,430 | 2,164,215 | AYALA PHARMACEUTICALS, INC. | 09 Apr 2025 |
As of 30 Jun 2026, 30 institutional investors reported holding 2,896,073 shares of OS Therapies Inc - Common Stock, par value $0.001 per share (OSTX). This represents 9.2% of the company’s total 31,500,824 outstanding shares.
Quarter history
Holder count, reported shares/value, and median price by quarter.
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 2,896,073 | $5,502,568 | +$35,275 | $1.90 | 30 |
| 2026 Q1 | 2,897,570 | $4,085,860 | +$1,489,526 | $1.41 | 29 |
| 2025 Q4 | 1,775,269 | $2,485,357 | +$236,334 | $1.40 | 24 |
| 2025 Q3 | 1,563,221 | $3,065,164 | +$1,884,295 | $1.96 | 25 |
| 2025 Q2 | 603,727 | $1,134,576 | +$402,668 | $1.88 | 13 |
| 2025 Q1 | 389,286 | $599,294 | +$293,725 | $1.54 | 6 |
| 2024 Q4 | 145,004 | $620,617 | +$9,243 | $4.28 | 5 |
| 2024 Q3 | 160,043 | $447,782 | +$447,782 | $2.80 | 7 |